参考文献
[1] Li J,Li X,Wang Q,et al. ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data[J]. Lancet,2015,385(9966):441-451.DOI: 10.1016/S0140-6736(14)60921-1.
[2] Chin CT, Ong TK, Krittayaphong R, et al. Characteristics and outcomes of medically managed patients with nonST-segment elevation acute coronary syndromes: insights from the multinational EPICOR Asia study[J]. Int J Cardiol, 2017,243:15-20. DOI: 10.1016/j.ijcard.2017.04.059.
[3] Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)[J]. Am Heart J, 2006,152(4):627-635. DOI: 10.1016/j.ahj.2006.04.012.
[4] Wallentin L, Becker RC, Budaj A,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med, 2009,361(11):1045-1057. DOI: 10.1056/NEJMoa0904327.
[5] Bonaca MP, Storey RF, Theroux P, et al. Efficacy and safety of
ticagrelor over time in patients with prior MI in PEGASUSTIMI 54[J]. J Am Coll Cardiol,2017,70(11):1368-1375. DOI: 10.1016/j.jacc.2017.07.768.
[6] Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without Aspirin in high-risk patients after PCI[J]. N Engl J Med, 2019,381(21):2032-2042. DOI: 10.1056/NEJMoa1908419.
[7] Westerhout CM, Fu Y, Lauer MS, et al. Short- and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkers[J]. J Am Coll Cardiol, 2006,48(5):939-947. DOI: 10.1016/j.jacc.2006.04.085.
[8] Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the Management of Acute coronary Syndromes (ACS) in Patients Presenting without Persistent ST-segment Elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2011,32(23):2999-3054. DOI: 10.1093/eurheartj/ehr236.
[9] Palmerini T, Della Riva D, Benedetto U, et al. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients[J]. Eur Heart J, 2017,38(14):1034-1043. DOI: 10.1093/eurheartj/ehw627.
[10] Pandey A, McGuire DK, de Lemos JA, et al. Revascularization trends in patients with diabetes mellitus and multivessel coronary artery disease presenting with non-ST elevation myocardial infarction: insights from the National Cardiovascular Data Registry acute coronary treatment and intervention outcomes network registry-get with the guidelines (NCDR ACTION Registry-GWTG)[J]. Circ Cardiovasc Qual Outcomes, 2016,9(3):197-205. DOI: 10.1161/CIRCOUTCOMES.115.002084.
[11] Yadav M, Généreux P, Palmerini T, et al. SYNTAX score and the risk of stent thrombosis after percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: an ACUITY trial substudy[J]. Catheter Cardiovasc Interv, 2015,85(1):1-10. DOI:10.1002/ccd.25396.
[12] Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions[J]. Circulation, 2007,115(17):2344-2351. DOI:10.1161/CIRCULATIONAHA.106.685313.
[13] Giustino G, Chieffo A, Palmerini T, et al. efficacy and safety of dual antiplatelet therapy after complex PCI[J]. J Am Coll Cardiol, 2016,68(17):1851-1864. DOI: 10.1016/j.jacc.2016.07.760.
[14] Kotsia A, Brilakis ES, Held C, et al. Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: insights from the PLATelet inhibition and patient Outcomes (PLATO) trial[J]. Am Heart J, 2014,168(1):68-75.e2. DOI: 10.1016/j.ahj.2014.04.001.
[15] Jia H, Dai J, Hou J, et al. Effective anti-thrombotic therapy without stenting: intravascular optical coherence tomographybased management in plaque erosion (the EROSION study)[J]. Eur Heart J, 2017,38(11):792-800. DOI: 10.1093/eurheartj/ehw381.
[16] Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective[J]. Eur Heart J, 2015,36(19):1163-1170. DOI: 10.1093/eurheartj/ehu505.
[17] Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents[J]. N Engl J Med, 2014,371(23):2155-2166. DOI: 10.1056/NEJMoa1409312.
[18] Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events[J]. N Engl J Med, 2006,354(16):1706-1717. DOI: 10.1056/NEJMoa060989.
[19] Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction[J]. N Engl J Med, 2015,372(19):1791-1800. DOI:10.1056/NEJMoa 1500857.
[20] Zhou M, Liu J, Hao Y, et al. Prevalence and in-hospital outcomes of diabetes among patients with acute coronary syndrome in China: findings from the improving care for cardiovascular disease in China-Acute Coronary Syndrome Project[J]. Cardiovasc Diabetol, 2018,17(1):147. DOI:10.1186/s12933-018-0793-x.
[21] Butler J, Hamo CE, Filippatos G, et al. The potential role and rationale for treatment of heart failure with sodium-glucose co- transporter 2 inhibitors[J]. Eur J Heart Fail, 2017,19(11):1390-1400. DOI:10.1002/ejhf.933.
[22] Aronson D, Edelman ER. Coronary artery disease and diabetes mellitus[J]. Cardiol Clin, 2014,32(3):439-455. DOI: 10.1016/j.ccl.2014.04.001.
[23] Qin SY, Zhou Y, Jiang HX, et al. The association of diabetes mellitus with clinical outcomes after coronary stenting: a metaanalysis[J]. PLoS One,2013,8(9):e72710. DOI:10.1371/journal.pone.0072710.
[24] O’Donoghue ML, Vaidya A, Afsal R, et al. An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials[J]. J Am Coll Cardiol, 2012,60(2):106-111. DOI:10.1016/j.jacc.2012.02.059.
[25] Schramm TK, Gislason GH, Køber L, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people[J]. Circulation, 2008,117(15):1945-1954. DOI:10.1161/CIRCULATIONAHA. 107.720847.
[26] Marso SP, Mercado N, Maehara A, et al. Plaque composition and clinical outcomes in acute coronary syndrome patients with metabolic syndrome or diabetes[J]. JACC Cardiovasc Imaging, 2012,5(3 Suppl):S42-52. DOI: 10.1016/j.jcmg.2012.01.008.
[27] Low Wang CC, Hess CN, Hiatt WR, et al. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus-mechanisms, management, and clinical considerations[J]. Circulation, 2016,133(24):2459-2502. DOI: 10.1161/CIRCULATIONAHA.116.022194.
[28] Bhatt DL, Bonaca MP, Bansilal S, et al. Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54[J]. J Am Coll Cardiol, 2016,67(23):2732-2740. DOI: 10.1016/j.jacc.2016.03.529.
[29] James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial[J]. Eur Heart J, 2010,31(24):3006-3016. DOI: 10.1093/eurheartj/ehq325.
[30] Bhatt DL, Steg PG, Mehta SR, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMISPCI): a phase 3, placebo-controlled, randomised trial[J]. Lancet, 2019,394(10204):1169-1180. DOI: 10.1016/S0140-6736(19)31887-2.
[31] Al Suwaidi J, Reddan DN, Williams K, et al. Platelet Ⅱb/ Ⅲa antagonism for the reduction of acute coronary syndrome events in a global organization network. prognostic implications of abnormalities in renal function in patients with acute coronary syndromes[J]. Circulation, 2002,106(8):974-980. DOI: 10.1161/01.cir.0000027560.41358.b3.
[32] Hanna EB, Chen AY, Roe MT, et al. Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention[J]. JACC Cardiovasc Interv, 2011,4(9):1002-1008. DOI:10.1016/j.jcin.2011.05.022.
[33] James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial[J]. Circulation, 2010,122(11):1056-1067. DOI: 10.1161/CIRCULATIONAHA.109.933796.
[34] Stone GW, Witzenbichler B, Weisz G,et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study[J]. Lancet, 2013,382(9892):614-623. DOI: 10.1016/S0140-6736(13)61170-8.
[35] Gurbel PA, Erlinge D, Ohman EM, et al. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy[J]. JAMA, 2012,308(17):1785-1794. DOI: 10.1001/jama.2012.17312.
[36] 世界华人检验与病理医师协会 , 中国医师协会检验医师分会心血管检验医学专业委员会 . 血小板功能检测在急性冠状动脉综合征患者抗血小板治疗中的应用专家共识 [J].中华医学杂志 ,2018,98(22):1743-1751. DOI: 10.3760/cma.j.issn.0376-2491.2018.22.005.
[37] Levine GN, Jeong YH, Goto S, et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI[J]. Nat Rev Cardiol, 2014,11(10):597-606. DOI: 10.1038/nrcardio.2014.104.
[38] Jeong YH. “East asian paradox”: challenge for the current antiplatelet strategy of “one-guideline-fits-all races” in acute coronary syndrome[J]. Curr Cardiol Rep, 2014,16(5):485. DOI: 10.1007/s11886-014-0485-4.
[39] 中华医学会心血管病学会 . 2014 抗血小板药物治疗反应多样性临床检测和处理的中国专家建议 [J]. 临床荟萃 , 2015(4):366-366.
[40] Kolh P, Windecker S, Alfonso F,et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)[J]. Eur J Cardiothorac Surg, 2014,46(4):517-592. DOI: 10.1093/ejcts/ezu366.
[41] Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial[J]. Lancet, 2010,376(9749):1320-1328. DOI: 10.1016/S0140-6736(10)61274-3.
[42] Chan MY, Becker RC, Harrington RA, et al. Noninvasive, medical management for non-ST-elevation acute coronary syndromes[J]. Am Heart J, 2008,155(3):397-407. DOI: 10.1016/j.ahj.2007.11.014.
[43] Gao R, Patel A, Gao W, et al. Prospective observational study of acute coronary syndromes in China: practice patterns and outcomes[J]. Heart, 2008,94(5):554-560. DOI: 10.1136/hrt.2007.119750.
[44] Sugiyama T, Hasegawa K, Kobayashi Y, et al. Differential time trends of outcomes and costs of care for acute myocardial infarction hospitalizations by ST elevation and type of intervention in the United States, 2001-2011[J]. J Am Heart Assoc,2015,4(3):e001445. DOI:10.1161/JAHA.114.001445.
[45] AlHabib KF, Hersi A, Alsheikh-Ali AA, et al. Prevalence, predictors, and outcomes of conservative medical management in non-ST-segment elevation acute coronary syndromes in Gulf RACE-2[J]. Angiology, 2012,63(2):109-118. DOI: 10.1177/0003319711409200.
[46] Zhang B, Shen DP, Zhou XC, et al. Long-term prognosis of patients with acute non-ST-segment elevation myocardial infarction undergoing different treatment strategies[J]. Chin Med J (Engl), 2015,128(8):1026-1031. DOI: 10.4103/0366-6999.155071.